Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33.

Saved in:
Bibliographic Details
Title: Prohibitin expression is associated with high grade breast cancer but is not a driver of amplification at 17q21.33.
Authors: Webster LR; Sydney Medical School - Westmead, University of Sydney, Westmead †Westmead Institute for Cancer Research, Westmead ‡Westmead Millennium Institute, Westmead §Tissue Pathology, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead ||Translational Oncology, Sydney West Cancer Network, Western Sydney and Nepean Blue Mountains Local Health Districts, Westmead ¶Anatomical Pathology, St Vincent's Hospital, Darlinghurst **Prince of Wales Clinical School, University of New South Wales, Randwick ††School of Medical Sciences University of New South Wales, Randwick ‡‡School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia §§Genetics Branch, National Cancer Institute, Bethesda MD USA ||||these authors contributed equally to this work., Provan PJ, Graham DJ, Byth K, Walker RL, Davis S, Salisbury EL, Morey AL, Ward RL, Hawkins NJ, Clarke CL, Meltzer PS, Balleine RL
Source: Pathology [Pathology] 2013 Dec; Vol. 45 (7), pp. 629-36.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lippincott Williams & Wilkins Country of Publication: England NLM ID: 0175411 Publication Model: Print Cited Medium: Internet ISSN: 1465-3931 (Electronic) Linking ISSN: 00313025 NLM ISO Abbreviation: Pathology Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1465-3931
DOI:10.1097/PAT.0000000000000004